GeoVax Labs, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; unaudited. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies using its GV-MVA-VLP platform. Its programs include COVID-19, HIV, hemorrhagic fever viruses, malaria, Zika, and solid-tumor cancers. The company had no product-sales revenue.
Financial performance and position
| Metric | Q1 2021 | Q1 2020 / prior balance date |
|---|---|---|
| Grant and collaboration revenue | $110,417 | $715,977 |
| Research and development expense | $602,783 | $808,936 |
| General and administrative expense | $1,071,710 | $502,345 |
| Operating loss | $1,564,076 | $595,304 |
| Net loss | $1,562,778 | $595,694 |
| Net loss per share | $0.29 | $2.54 |
| Operating cash used | $1,621,027 | $358,620 |
| Cash and cash equivalents | $20,842,782 | $9,883,796 at Dec. 31, 2020 |
| Working capital | $20,509,263 | $9,424,839 at Dec. 31, 2020 |
| Total liabilities | $464,106 | $825,047 at Dec. 31, 2020 |
Operating margin and gross margin are not meaningful measures presented for this grant-funded, pre-commercial business; the filing does not provide a clear gross-margin value. Cash flow from financing was $12.58 million, mainly from a February stock offering ($9.41 million net) and warrant exercises ($3.17 million). Total debt was approximately $195,000, including current and long-term notes payable.
Material changes and drivers
- Revenue fell by about 85% year over year, primarily reflecting the timing and amount of grant-related expenditures. Q1 2021 revenue was from a COVID-19 NIH SBIR grant; Q1 2020 included Lassa fever grant and Leidos collaboration revenue.
- Net loss increased to $1.56 million from $0.60 million. R&D expense declined 25%, mainly due to timing of external grant expenditures, while reported G&A expense more than doubled. Management attributed the G&A increase partly to about $200,000 of higher Delaware franchise taxes, as well as legal and patent costs, consulting, and personnel costs.
- Cash increased substantially following equity financing and warrant exercises. Common shares outstanding rose to 6,315,467 at March 31 from 3,834,095 at year-end 2020, reflecting the offering and warrant exercises.
Outlook, risks, and notable items
- Management believes cash, existing government funding commitments, and clinical-trial support will fund planned operations into 2023. The company expects continued losses and may need additional financing; there is no assurance that funding will be available on acceptable terms.
- GeoVax reported four designed and constructed COVID-19 vaccine candidates being tested in relevant animal challenge models. Its HIV candidate GOVX-B11 was expected to enter the HVTN 132 trial in late 2021; other HIV combination-trial plans were also described. Timelines may be delayed, including by the COVID-19 pandemic.
- Management expects R&D costs to rise as programs advance, particularly into clinical trials, but did not provide project-level cost or timing estimates. G&A was expected to remain reasonably consistent with Q1 for the rest of 2021.
- Approximately $355,010 of approved grant funds remained available for 2021. Outstanding vendor and subcontractor purchase commitments were approximately $800,000, expected due in 2021; $211,326 was expected to be reimbursable under existing grants.
- The $170,200 PPP loan forgiveness application had not been processed as of the report. The office and laboratory lease runs through December 2022 but may be terminated by either party on 90 days’ written notice.
- The filing reports no material changes to previously disclosed risk factors, no legal proceedings, and no material changes in internal control over financial reporting. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Whether grant awards, trial support, and the expected runway into 2023 remain sufficient as research and clinical spending increases.
- Progress, funding, and timelines for the COVID-19 and HIV programs, including planned clinical trials and any pandemic-related delays.
- Future financing needs and potential dilution, given the increased share count and outstanding warrants and options.
- Status of the PPP loan forgiveness application and collection/reimbursement of grant-supported costs.
- The filing gives inconsistent figures for warrants exercised on a cashless basis: 188,668 in the supplemental cash-flow disclosure versus 188,688 in the stockholders’ equity note.